MCID: THY029
MIFTS: 51

Thyroid Carcinoma

Categories: Cancer diseases, Endocrine diseases, Rare diseases

Aliases & Classifications for Thyroid Carcinoma

MalaCards integrated aliases for Thyroid Carcinoma:

Name: Thyroid Carcinoma 58 29 54 6 17
Thyroid Cancer 36 29 54 42

Characteristics:

Orphanet epidemiological data:

58
thyroid carcinoma
Prevalence: 6-9/10000 (Europe),1-5/10000 (United States),1-9/100000 (Worldwide),1-5/10000 (Worldwide); Age of onset: Adult;

Classifications:

Orphanet: 58  
Rare endocrine diseases


External Ids:

KEGG 36 H00032
UMLS via Orphanet 72 C0549473
Orphanet 58 ORPHA100088

Summaries for Thyroid Carcinoma

MedlinePlus : 42 Your thyroid is a butterfly-shaped gland in your neck, just above your collarbone. It makes hormones that help the body work normally. There are several types of cancer of the thyroid gland. You are at greater risk if you Are between ages 25 and 65 Are a woman Are Asian Have a family member who has had thyroid disease Have had radiation treatments to your head or neck You should see a doctor if you have a lump or swelling in your neck. Doctors use a physical exam, thyroid tests, other blood and imaging tests, and a biopsy to diagnose thyroid cancer. Treatment depends on the type of cancer you have and how far the cancer has spread. Many patients receive a combination of treatments. They may include surgery, radioactive iodine, hormone treatment, radiation therapy, chemotherapy, or targeted therapy. Targeted therapy uses drugs or other substances that attack specific cancer cells with less harm to normal cells. NIH: National Cancer Institute

MalaCards based summary : Thyroid Carcinoma, also known as thyroid cancer, is related to thyroid carcinoma, familial medullary and thyroid gland anaplastic carcinoma, and has symptoms including tinnitus, snoring and sore throat. An important gene associated with Thyroid Carcinoma is RET (Ret Proto-Oncogene), and among its related pathways/superpathways are Thyroid cancer and Transcriptional misregulation in cancer. The drugs Lenvatinib and Guaifenesin have been mentioned in the context of this disorder. Affiliated tissues include thyroid, lymph node and pituitary.

KEGG : 36 Thyroid cancer is the most common endocrine malignancy and accounts for the majority of endocrine cancer- related deaths each year. More than 95% of thyroid carcinomas are derived from follicular cells. Their behavior varies from the indolent growing, well-differentiated papillary and follicular carcinomas (PTC and FTC, respectively) to the extremely aggressive undifferentiated carcinoma (UC). Somatic rearrangements of RET and TRK are almost exclusively found in PTC and may be found in early stages. The most distinctive molecular features of FTC are the prominence of aneuploidy and the high prevalence of RAS mutations and PAX8-PPAR{gamma} rearrangements. p53 seems to play a crucial role in the dedifferentiation process of thyroid carcinoma.

Related Diseases for Thyroid Carcinoma

Diseases related to Thyroid Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1084)
# Related Disease Score Top Affiliating Genes
1 thyroid carcinoma, familial medullary 33.3 RET NKX2-1 MALAT1 BRAF
2 thyroid gland anaplastic carcinoma 32.9 TSHR RET NKX2-1 BRAF
3 differentiated thyroid carcinoma 32.9 TSHR RET NKX2-1 BRAF
4 thyroid gland follicular carcinoma 32.7 TSHR RET NKX2-1 BRAF
5 thyroid cancer, nonmedullary, 1 32.5 PVT1 PTCSC3 NKX2-1 NEAT1 MALAT1 HOTAIR
6 papillary carcinoma 32.2 TSHR RET NKX2-1 BRAF
7 goiter 32.1 TSHR RET NKX2-1
8 thyroid tumor 32.0 RET BRAF
9 nodular goiter 31.7 TSHR RET BRAF
10 hypothyroidism 31.6 TSHR RET NKX2-1 BRAF
11 follicular adenoma 31.6 TSHR RET NKX2-1 BRAF
12 thyroid gland cancer 31.5 TSHR RET NKX2-1 BRAF
13 thyroid gland disease 31.4 TSHR RET NKX2-1
14 hashimoto thyroiditis 31.4 TSHR RET BRAF
15 papillary thyroid microcarcinoma 31.4 TSHR NKX2-1 BRAF
16 struma ovarii 31.2 TSHR RET NKX2-1 BRAF
17 malignant struma ovarii 31.0 RET NKX2-1
18 ovarian germ cell teratoma 31.0 RET NKX2-1
19 adenocarcinoma 30.8 RET NKX2-1 MALAT1 H19 BRAF
20 pituitary adenoma 30.6 MALAT1 HOTAIR H19
21 thyroid gland papillary carcinoma 30.6 GAS5 BRAF
22 postsurgical hypothyroidism 30.5 TSHR RET
23 benign struma ovarii 30.4 TSHR RET NKX2-1 BRAF
24 athyreosis 30.1 TSHR NKX2-1
25 tall cell variant papillary carcinoma 30.1 RET NKX2-1 BRAF
26 spitzoid melanoma 30.1 RET BRAF
27 squamous cell carcinoma 30.0 UCA1 NEAT1 MALAT1 HOTAIR H19 CDKN2B-AS1
28 gastric adenocarcinoma 30.0 NEAT1 HOTAIR H19 BRAF
29 b-cell lymphoma 29.9 PVT1 MALAT1 HOTAIR GAS5
30 laryngeal squamous cell carcinoma 29.9 NEAT1 MALAT1 HOTAIR H19 CDKN2B-AS1
31 small cell cancer of the lung 29.8 NKX2-1 MALAT1 HOTAIR
32 malignant pleural mesothelioma 29.8 PVT1 NKX2-1 GAS5
33 leukemia, chronic myeloid 29.8 UCA1 HOTAIR H19 BRAF
34 retinitis pigmentosa 11 29.6 UCA1 PVT1 NEAT1 HOTAIR GAS5
35 oral squamous cell carcinoma 29.6 UCA1 NEAT1 MALAT1 HOTAIR H19
36 glioblastoma 29.6 MALAT1 HOTAIR H19 GAS5 BRAF
37 kidney cancer 29.6 PVT1 MALAT1 HOTAIR H19 GAS5
38 lung cancer susceptibility 3 29.5 NKX2-1 MALAT1 HOTAIR H19 GAS5 CASC2
39 melanoma 29.5 UCA1 PVT1 MALAT1 HOTAIR H19 GAS5
40 leukemia 29.2 NEAT1 MLF1 HOTAIR GAS5 CDKN2B-AS1 BRAF
41 tongue squamous cell carcinoma 29.1 UCA1 MALAT1 AFAP1-AS1
42 pancreatic ductal adenocarcinoma 29.1 UCA1 PVT1 MALAT1 HOTAIR H19 AFAP1-AS1
43 leukemia, acute myeloid 29.0 UCA1 MLF1 MALAT1 HOTAIR CDKN2B-AS1
44 cholangiocarcinoma 29.0 UCA1 PANDAR NEAT1 MALAT1 H19 BRAF
45 esophageal cancer 29.0 UCA1 PVT1 MALAT1 HOTAIR H19 GAS5
46 endometrial cancer 29.0 UCA1 RET NKX2-1 NEAT1 HOTAIR H19
47 myeloma, multiple 28.9 UCA1 PVT1 NKX2-1 MALAT1 HOTAIR H19
48 renal cell carcinoma, nonpapillary 28.8 UCA1 RET PVT1 PANDAR NKX2-1 MALAT1
49 high grade glioma 28.5 PVT1 NEAT1 MALAT1 HOTAIR H19 GAS5
50 osteogenic sarcoma 28.3 UCA1 PVT1 PANDAR NEAT1 MALAT1 HOTAIR

Graphical network of the top 20 diseases related to Thyroid Carcinoma:



Diseases related to Thyroid Carcinoma

Symptoms & Phenotypes for Thyroid Carcinoma

UMLS symptoms related to Thyroid Carcinoma:


tinnitus, snoring, sore throat, coughing, vertigo/dizziness, equilibration disorder

Drugs & Therapeutics for Thyroid Carcinoma

Drugs for Thyroid Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 251)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lenvatinib Approved, Investigational Phase 4 417716-92-8
2
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
3
Acetaminophen Approved Phase 4 103-90-2 1983
4
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
5
Codeine Approved, Illicit Phase 4 76-57-3 5284371
6
Selenium Approved, Investigational, Vet_approved Phase 4 7782-49-2
7 Analgesics, Non-Narcotic Phase 4
8 Analgesics Phase 4
9 Respiratory System Agents Phase 4
10 Narcotics Phase 4
11 Antitussive Agents Phase 4
12 Analgesics, Opioid Phase 4
13 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
14 Antipyretics Phase 4
15 Protective Agents Phase 4
16 Selenium Supplement Phase 4
17 Antioxidants Phase 4
18
Sorafenib Approved, Investigational Phase 3 284461-73-0 216239 406563
19 Hemostatics Phase 3
20 Coagulants Phase 3
21 Fibrin Tissue Adhesive Phase 3
22 Hormones Phase 3
23
Apatinib Phase 3 811803-05-1
24 Hormone Antagonists Phase 3
25
Rosiglitazone Approved, Investigational Phase 2 122320-73-4 77999
26
Pemetrexed Approved, Investigational Phase 2 150399-23-8, 137281-23-3 446556 60843
27
Levoleucovorin Approved, Investigational Phase 2 68538-85-2 149436
28
Loperamide Approved Phase 1, Phase 2 53179-11-6 3955
29
Fluorouracil Approved Phase 2 51-21-8 3385
30
Axitinib Approved, Investigational Phase 2 319460-85-0 6450551
31
Panobinostat Approved, Investigational Phase 2 404950-80-7 6918837
32
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
33
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
34
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
35
Azacitidine Approved, Investigational Phase 2 320-67-2 9444
36
Decitabine Approved, Investigational Phase 2 2353-33-5 451668
37
Histamine Approved, Investigational Phase 1, Phase 2 51-45-6, 75614-87-8 774
38
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
39
Calcium carbonate Approved, Investigational Phase 2 471-34-1
40
Nintedanib Approved Phase 2 656247-17-5 56843413
41
Somatostatin Approved, Investigational Phase 2 51110-01-1, 38916-34-6 53481605
42
Pasireotide Approved Phase 2 396091-73-9 9941444
43
Salicylic acid Approved, Investigational, Vet_approved Phase 2 69-72-7 338
44
Pioglitazone Approved, Investigational Phase 2 111025-46-8 4829
45
Hydroxyurea Approved Phase 2 127-07-1 3657
46
Iodine Approved, Investigational Phase 2 7553-56-2 807
47
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
48
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
49
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
50
Benzocaine Approved, Investigational Phase 2 1994-09-7, 94-09-7 2337

Interventional clinical trials:

(show top 50) (show all 486)
# Name Status NCT ID Phase Drugs
1 The Use of Lu177 in the Treatment of Progressive and Unresectable Metastatic Medullary Thyroid Cancer Unknown status NCT01915485 Phase 4
2 Is it Possible to Increase Quality of Life, Using Recombinant TSH Instead of Withdrawal of Thyroid Hormone Treatment, Before Iodine Uptake in Patients With Thyroid Cancer? Completed NCT00604318 Phase 4 rhTSH
3 Diagnostic Accuracy Study of Indocyanine Green for Parathyroid Perfusion Assessment Completed NCT03969108 Phase 4 Indocyanine Green
4 Prospective Single Arm Post Marketing Phase IV Study to Assess the Safety and Efficacy of Lenvatinib in Subjects With Locally Recurrent or Metastatic, Progressive, Radioiodine Refractory Differentiated Thyroid Cancer Recruiting NCT03573960 Phase 4 Lenvatinib
5 An International, Randomised, Double-Blind, Two-Arm Study To Evaluate The Safety And Efficacy Of Vandetanib 150 And 300mg/Day In Patients With Unresectable Locally Advanced Or Metastatic Medullary Thyroid Carcinoma With Progressive Or Symptomatic Disease Active, not recruiting NCT01496313 Phase 4 300mg vandetanib;150mg vandetanib
6 A Randomized, Double-blind Study To Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared to a 140 mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients Active, not recruiting NCT01896479 Phase 4 Cabozantinib (XL184) 140 mg;Cabozantinib (XL184) 60 mg;Placebo tablet;Placebo capsule
7 Minimizing Narcotic Analgesics After Thyroid or Parathyroid Surgery Active, not recruiting NCT03469310 Phase 4 Acetaminophen 500Mg Cap;Tylenol #3 Oral Tablet;Tramadol
8 Distribution of Selenium in Patients With Differentiated Thyroid Carcinoma and Effect of Selenium Supplement on Prognosis of Patients With Differentiated Thyroid Carcinoma. Not yet recruiting NCT04683575 Phase 4 Selenium Yeast;Placebo
9 Levothyroxine Replacement With Liquid Gel Capsules or Tablets in Post-thyroidectomy Stage in Low Risk Differentiated Thyroid Cancer Patients Terminated NCT02946918 Phase 4 Levothyroxine
10 Phase Ⅱ Non-randomized Multicenter Controlled Trial About Effect of Remnant Ablation Therapy on the Recurrence in Low-risk Differentiated Thyroid Cancer Patients Unknown status NCT02418247 Phase 2, Phase 3 I131;I123
11 Medico-Economic Comparison of Four Strategies of Radioiodine Ablation in Thyroid Carcinoma Patients - Estimabl Unknown status NCT00435851 Phase 3 Thyrogen, thyroid hormone withdrawal, iode 131
12 Sentinel Lymph Node Biopsy in the Thyroid Carcinoma; Randomized, Prospective Study Unknown status NCT01149161 Phase 2, Phase 3
13 Decision Aid on Radioactive Iodine Treatment for Early Stage Papillary Thyroid Cancer (Randomized Controlled Trial) Completed NCT01083550 Phase 2, Phase 3
14 The Role of Sentinel Lymph Node Biopsy (SLNB) In the Management of Differentiated Thyroid Cancer Completed NCT00794053 Phase 3
15 Efficacy of Fibrin Sealant to Reduce the Amount of Postoperative Drain in Patients With Harmonic Scalpel-assisted Total Thyroidectomy With Anterior Compartment Neck Dissections Completed NCT01126060 Phase 3 Usage of Fibrin sealant
16 A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Compare the Efficacy and Safety of Anlotinib Versus Placebo in Patients With Medullary Thyroid Carcinoma(ALTER01031) Completed NCT02586350 Phase 2, Phase 3 Anlotinib;Placebo
17 Value of Sentinel Lymph Node Biopsy to Lateral Neck Lymph Node in Thyroid Carcinoma: Prospective Study Completed NCT01137097 Phase 2, Phase 3
18 Phase 3 Trial of Adjuvant External Beam Radiotherapy for Locally Invasive Differentiated Thyroid Carcinoma Completed NCT00144079 Phase 3
19 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer Completed NCT01321554 Phase 3 Lenvatinib;Placebo;Lenvatinib
20 An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 Versus Placebo in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer Completed NCT00704730 Phase 3 XL184;Placebo
21 Follow-up of Thyroid Cancer Patients From Study THYR-008-00 Who Received Thyroid Remnant Ablation Using Either the Hypothyroid or the Thyrogen Method. Completed NCT00295763 Phase 3 Thyrogen (thyrotropin alfa for injection)
22 Efficacy of Subfascial Approach in Thyroidectomy to Quality of Life in Thyroid Disease Patients: Prospective Randomized Study Completed NCT01616316 Phase 2, Phase 3
23 Prophylactic Central Lymph Node Dissection in Papillary Thyroid Microcarcinoma: A Prospective Randomized Controlled Trial Completed NCT00795782 Phase 3
24 A Double-Blind Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer Completed NCT00984282 Phase 3 Sorafenib (Nexavar, BAY43-9006);Placebo
25 Differentiated Thyroid Cancer: is There a Need for Radioiodine Ablation in Low Risk Patients? Recruiting NCT01837745 Phase 3 rhTSH stimulation;I131
26 A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531) Recruiting NCT04211337 Phase 3 Selpercatinib;Cabozantinib;Vandetanib
27 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects With Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR-Targeted Therapy Recruiting NCT03690388 Phase 3 Cabozantinib;Placebo
28 A Multicenter, Randomized, Double-Blind,Placebo-controlled,Phase 3 Trial of Donafenib in 131IRefractory Differentiated Thyroid Cancer Recruiting NCT03602495 Phase 3 Donafenib;Placebo
29 Multicentric Phase III Trial Comparing Two Strategies in Intermediate-risk Differentiated Thyroid Cancer Patients: Systematic Radioiodine Administration (3.7 GBq I131 After rhTSH) Versus Decision of Radioiodine Treatment Guided by a Post-operative Work-up Based on Serum Tg Values and Diagnostic RAI Scintigraphy Recruiting NCT04290663 Phase 3 Systematic RAI-treatment
30 A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA™; SAR390530 (Formerly AstraZeneca ZD6474)) 300 mg in Patients With Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy. Active, not recruiting NCT01876784 Phase 3 Vandetanib (SAR390530);Placebo
31 A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Compare the Efficacy and Safety of Anlotinib Versus Placebo in Patients With 131I-Refractory Differentiated Thyroid Cancer(ALTER01032) Active, not recruiting NCT02586337 Phase 2, Phase 3 Anlotinib;Placebo
32 An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMATM) Versus Placebo in Subjects With Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer Active, not recruiting NCT00410761 Phase 3 ZD6474 (Vandetanib)
33 Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients Active, not recruiting NCT01398085 Phase 2, Phase 3
34 A Randomized,Int.,Open-Label Phase III Study to Assess the Effect of a Patient Outreach Program on the Percentage of Time Patients With Locally Advanced or Metastatic MTC Experience Grade 2 or Higher AEs in the First 12 Months of Treatment With Vandetanib Active, not recruiting NCT01298323 Phase 3 Vandetanib
35 A Randomized, Double-Blind, Placebo-Controlled Study of Apatinib in Locally Advanced or Metastatic Radioactive Iodine-refractory Differentiated Thyroid Cancer Active, not recruiting NCT03048877 Phase 3 Apatinib Oral Tablet;Placebo Oral Tablet
36 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131 I-Refractory Differentiated Thyroid Cancer in China Active, not recruiting NCT02966093 Phase 3 Lenvatinib;Placebo
37 Multicentre Randomised Trial of High Dose Versus Low Dose Radioiodine, With or Without Recombinant Human Thyroid Stimulating Hormone, for Remnant Ablation Following Surgery for Differentiated Thyroid Cancer [HILO] Active, not recruiting NCT00415233 Phase 3
38 ESTIMation of the ABiLity of Prophylactic Central Compartment Neck Dissection to Modify Outcomes in Low-risk Differentiated Thyroid Cancer Not yet recruiting NCT03570021 Phase 3
39 A Phase II/III Study to Evaluate the Safety and Efficacy of Combretastatin A-4 Phosphate in Combination With Paclitaxel and Carboplatin in Comparison With Paclitaxel and Carboplatin Against Anaplastic Thyroid Carcinoma [FACT] Terminated NCT00507429 Phase 2, Phase 3 CA4P;paclitaxel;carboplatin
40 A Randomised, Double Blind Study to Compare the Complete Remission Rate Following a 5-Week Course of Selumetinib or Placebo and Single Dose Adjuvant Radioactive Iodine Therapy in Patients With Differentiated Thyroid Cancer Terminated NCT01843062 Phase 3 Selumetinib;Placebo;Radioactive Iodine Therapy
41 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Fosbretabulin Tromethamine (CA4P) in Combination With Paclitaxel and Carboplatin in Anaplastic Thyroid Carcinoma (FACT2) Withdrawn NCT01701349 Phase 3 Fosbretabulin + paclitaxel + carboplatin;Placebo + paclitaxel + carboplatin
42 Prospective Study of Nexavar for Neoadjuvant Treatment of Anaplastic Thyroid Cancer Unknown status NCT03565536 Phase 2 Nexavar
43 A Prospective, Multicenter, Open Label Phase Ⅱ Clinical Trial of Doxorubicin Hydrochloride Liposome Injection Combined With Cisplatin in the Treatment of Advanced Poorly Differentiated Thyroid Carcinoma Unknown status NCT03387943 Phase 2 PLD;Cisplatin
44 The Effectiveness and Safety of Apatinib Mesylate in Locally Advanced/Metastatic Differentiated Thyroid Carcinoma: a Phase 2 Trial. Unknown status NCT03167385 Phase 2 Apatinib Mesylate
45 A Phase II Study to Investigate the Efficacy of RAD001 (Afinitor®, Everolimus) in Patients With Irresectable Recurrent or Metastatic Differentiated, Undifferentiated (Anaplastic) and Medullary Thyroid Carcinoma Unknown status NCT01118065 Phase 2 everolimus
46 Intensity Modulated Radiation Therapy Combined With Apatinib for Inoperable or Iodine Refractory Thyroid Cancer: A Phase II Single-arm Study Unknown status NCT03300765 Phase 2 Apatinib
47 Evaluation of the Effect of Carum Carvi on Levels of Plasma Thyroid Hormones and TSH Level in Patients on Thyroid Hormone Therapy and Normal Controls. Unknown status NCT01471288 Phase 1, Phase 2 Carum Cravi;Placebo
48 Phase 2 Trial of Pemetrexed (Alimta™) Combined With Paclitaxel in Patients With Recurrent/Advanced Follicular, Papillary or Anaplastic Thyroid Cancer Unknown status NCT00786552 Phase 2 pemetrexed + paclitaxel
49 A Multicenter Phase II Pilot Open Label Study to Evaluate the Efficacy and Safety of BKM120 in the Treatment of Patients With Advanced or Metastatic Differentiated Thyroid Cancers Unknown status NCT01830504 Phase 2 BKM120
50 The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer Unknown status NCT01739634 Phase 1, Phase 2 CASAD

Search NIH Clinical Center for Thyroid Carcinoma

Genetic Tests for Thyroid Carcinoma

Genetic tests related to Thyroid Carcinoma:

# Genetic test Affiliating Genes
1 Thyroid Cancer 29
2 Thyroid Carcinoma 29

Anatomical Context for Thyroid Carcinoma

MalaCards organs/tissues related to Thyroid Carcinoma:

40
Thyroid, Lymph Node, Pituitary, Endothelial, Bone, Salivary Gland, Trachea

Publications for Thyroid Carcinoma

Articles related to Thyroid Carcinoma:

(show top 50) (show all 38624)
# Title Authors PMID Year
1
Metastatic-prone telomerase reverse transcriptase (TERT) promoter and v-Raf murine sarcoma viral oncogene homolog B (BRAF) mutated tall cell variant of papillary thyroid carcinoma arising in ectopic thyroid tissue: A case report. 42 61
33466206 2021
2
Papillary Thyroid Carcinoma BRAF Immunopositivity. 61 42
33413831 2021
3
Postoperative outcomes of free myocutaneous flap and pedicled myocutaneous flap for reconstruction in locally invasive thyroid carcinoma. 61 42
33466165 2021
4
INSL3 has tumor-promoting activity in thyroid cancer. 61 54
19950223 2010
5
Targeted therapy for thyroid cancer: An updated review of investigational agents. 61 54
20496261 2010
6
Cytokines, thyroid diseases and thyroid cancer. 61 54
20381375 2010
7
The type 2 deiodinase Thr92Ala polymorphism is associated with increased bone turnover and decreased femoral neck bone mineral density. 61 54
20200941 2010
8
Allelic variant at -79 (C>T) in CDKN1B (p27Kip1) confers an increased risk of thyroid cancer and alters mRNA levels. 54 61
20075119 2010
9
RAS mutation-positive follicular variant of papillary thyroid carcinoma arising in a struma ovarii. 61 54
19898969 2010
10
The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors. 54 61
19897009 2010
11
Iodine induces apoptosis via regulating MAPKs-related p53, p21, and Bcl-xL in thyroid cancer cells. 61 54
20138958 2010
12
Diagnostic utility of galectin-3 in thyroid cancer. 61 54
20363921 2010
13
Relaxin enhances S100A4 and promotes growth of human thyroid carcinoma cell xenografts. 61 54
20332215 2010
14
Pathogenesis of thyroid eye disease--does autoimmunity against the TSH receptor explain all cases? 54 61
20464711 2010
15
Thioredoxin and thioredoxin reductase expression in thyroid cancer depends on tumour aggressiveness. 54 61
20392995 2010
16
Erlotinib enhances the proapoptotic activity of cytotoxic agents and synergizes with paclitaxel in poorly-differentiated thyroid carcinoma cells. 61 54
20332457 2010
17
Low thyroglobulin concentrations after thyroidectomy increase the prognostic value of undetectable thyroglobulin levels on levo-thyroxine suppressive treatment in low-risk differentiated thyroid cancer. 61 54
19636213 2010
18
XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC. 61 54
20127563 2010
19
Encapsulated thyroid tumors of follicular cell origin with high grade features (high mitotic rate/tumor necrosis): a clinicopathologic and molecular study. 61 54
19913280 2010
20
Small (<10 mm) thyroid nodules; how aggressively should they be managed? 61 54
20164665 2010
21
Is there any venous gradient in serum thyroglobulin levels in patients with differentiated thyroid cancer? 61 54
20353278 2010
22
Recent advances in the research and development of B-Raf inhibitors. 54 61
20345352 2010
23
Selectively targeting mutant BRAF in thyroid cancer. 61 54
20056810 2010
24
Standard and emerging therapies for metastatic differentiated thyroid cancer. 61 54
20142332 2010
25
The level of TSH appeared favourable in maintaining bone mineral density in postmenopausal women. 61 54
20151763 2010
26
Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin? 54 61
20017617 2010
27
Detection of circulating thyroid cancer cells in patients with thyroid microcarcinomas. 61 54
19958935 2009
28
Clinical inquiries. What's the best way to monitor low-risk patients with a history of differentiated thyroid cancer? 61 54
19961815 2009
29
Targeting the RET pathway in thyroid cancer. 54 61
19934298 2009
30
[Usefulness of the determination of thyroglobulin in lymph node aspirates of patients with papillary thyroid carcinoma and positive antithyroglobulin antibodies]. 61 54
20096208 2009
31
F-18 FDG-PET/CT evaluation of patients with differentiated thyroid cancer with negative I-131 total body scan and high thyroglobulin level. 54 61
19851169 2009
32
Evaluation of 18fluoro-2-deoxyglucose positron emission tomography in iodine scan negative, differentiated thyroid cancer recurrence. 61 54
19607742 2009
33
Kinase expression and chromosomal rearrangements in papillary thyroid cancer tissues: investigations at the molecular and microscopic levels. 54 61
20083851 2009
34
Ablative free thyroxine to thyroglobulin ratio as a predictor of differentiated thyroid cancer recurrence. 54 61
19769825 2009
35
Significance of marginally elevated calcitonin levels in micromedullary thyroid cancer. 54 61
19636626 2009
36
Serum thyroglobulin measurement in the follow-up of patients treated for differentiated thyroid cancer. 61 54
19910901 2009
37
Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations. 54 61
19878585 2009
38
Radioiodine ablation: when and how. 61 54
19910900 2009
39
BRAF V600E mutation analysis increases diagnostic accuracy for papillary thyroid carcinoma in fine-needle aspiration biopsies. 61 54
19574281 2009
40
Results of rosiglitazone therapy in patients with thyroglobulin-positive and radioiodine-negative advanced differentiated thyroid cancer. 54 61
19678746 2009
41
Charcoal suspension tattoo localization for differentiated thyroid cancer recurrence. 54 61
19551443 2009
42
Molecularly targeted therapies for thyroid cancers. 54 61
19546052 2009
43
A microfluidic biosensor based on competitive protein adsorption for thyroglobulin detection. 61 54
19577460 2009
44
Regulation of uptake of 18F-FDG by a follicular human thyroid cancer cell line with mutation-activated K-ras. 61 54
19652218 2009
45
Is transketolase like 1 a target for the treatment of differentiated thyroid carcinoma? A study on thyroid cancer cell lines. 61 54
18806930 2009
46
Cell surface and secreted protein profiles of human thyroid cancer cell lines reveal distinct glycoprotein patterns. 54 61
19530676 2009
47
Re-differentiation of thyroid carcinoma cell lines treated with 5-Aza-2'-deoxycytidine and retinoic acid. 54 61
19524134 2009
48
Urokinase receptor, MMP-1 and MMP-9 are markers to differentiate prognosis, adenoma and carcinoma in thyroid malignancies. 61 54
19480010 2009
49
RET/PTC rearrangements arising from a small population of papillary thyroid carcinoma cells, possible candidate for passenger mutation. 54 61
19495791 2009
50
Epigenetic silencing of TTF-1/NKX2-1 through DNA hypermethylation and histone H3 modulation in thyroid carcinomas. 54 61
19506552 2009

Variations for Thyroid Carcinoma

ClinVar genetic disease variations for Thyroid Carcinoma:

6
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 RET NM_020975.6(RET):c.1900T>C (p.Cys634Arg) SNV Pathogenic 13917 rs75076352 10:43609948-43609948 10:43114500-43114500

Copy number variations for Thyroid Carcinoma from CNVD:

7 (show all 22)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 48476 11 1 43400000 Gain Thyroid cancer
2 75266 13 18400000 72100000 Loss Thyroid cancer
3 80538 13 93800000 114142980 Loss Thyroid cancer
4 85051 14 37800000 43500000 Copy number FOXA1 Thyroid cancer
5 96631 15 90931472 91045475 Amplificationlication IQGAP1 Thyroid cancer
6 111285 17 35400000 68400000 Gain Thyroid cancer
7 120295 18 23300000 71300000 Loss Thyroid cancer
8 150420 20 1 27100000 Amplification Thyroid cancer
9 151957 20 27100000 62435964 Amplification Thyroid cancer
10 153452 20 37100000 62435964 Gain Thyroid cancer
11 171643 3 170900000 182700000 Gain PIK3CA Thyroid cancer
12 171644 3 170900000 182700000 Gain PIK3CA Thyroid cancer
13 191662 5 1 45800000 Amplification Thyroid cancer
14 191664 5 1 45800000 Gain Thyroid cancer
15 200481 5 55800000 180857866 Gain Thyroid cancer
16 201091 5 65300000 159900000 Amplification Thyroid cancer
17 217036 7 1 158821424 Amplification Thyroid cancer
18 230743 8 1 19100000 Loss Thyroid cancer
19 236403 8 16100000 117700000 Amplification Thyroid cancer
20 236404 8 16100000 146274826 Gain Thyroid cancer
21 261707 X 24900000 59500000 Loss Thyroid cancer
22 303365 21 26028751 26066642 Deletion GABPA Thyroid cancer

Expression for Thyroid Carcinoma

Search GEO for disease gene expression data for Thyroid Carcinoma.

Pathways for Thyroid Carcinoma

Pathways related to Thyroid Carcinoma according to KEGG:

36
# Name Kegg Source Accession
1 Thyroid cancer hsa05216
2 Transcriptional misregulation in cancer hsa05202

Pathways related to Thyroid Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 9.7 UCA1 HOTAIR

GO Terms for Thyroid Carcinoma

Biological processes related to Thyroid Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 thyroid gland development GO:0030878 9.16 NKX2-1 BRAF
2 inner ear receptor cell stereocilium organization GO:0060122 8.96 TSHR SDC4
3 myeloid progenitor cell differentiation GO:0002318 8.62 MLF1 BRAF

Sources for Thyroid Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....